Hello All..especially HAL,
I have been a periodic poster on board for past 2 years. ITP diagnosed since 2017 and had splenectomy in March 2019, I am stable with platelets that hover between 35k and 70k plus I tried every treatment in book prior to surgery. (Did have indium scan done when I flew to London prior to surgery). Regardless, I have some fascinating news. There is a drug that will revolutionize how we treat coronavirus. It is called Leronlimab, a CCR5 blocker that you will hear within next few weeks. Coronavirus creates havoc in body due to significantly high levels (up to 100 times normal level )of the protein RANTES in blood. Leronlimab brings this protein back down to normal and restores immune homeostasis. The viral load goes down to 0 after once per week injections totaling 2 weeks. The reason why I am talking about RANTES and ITP is based on the research below:
There have been medical journals that indicate the elevated RANTES levels in individuals with ITP after doing extensive testing on plasma chemokine levels.
In reference to a specific medical journal, "Significance of Chemokines and Soluble CD40 Ligand in Patients with Autoimmune Thrombocytopenic Purpura" it indicates the following:
We investigated the levels of various chemokines and soluble CD40L (sCD40L) in ITP patients, in order to determine the influence of CD40-CD40L interaction on the pathogenesis of ITP. We found increases in MCP-1 and RANTES levels in ITP patients compared with those in healthy individuals. Thirty-eight of the 65 ITP patients (58.5%) had elevated levels of sCD40L. We found significant decreases in platelet counts in sCD40L-positive ITP patients. Although the sCD40L level did not differ significantly between the control and nonimmune thrombocytopenia groups, but among ITP patients. sCD40L level was significantly higher in those with untreated ITP than in those with treated ITP. In addition, significant increases in RANTES, MCP-1, sCD14, and sP-selectin levels were observed in sCD40L-positive ITP patients, although sE-selectin levels were not increased in such patients. For other factors examined, however, there were no differences in level between sCD40L-positive and -negative ITP patients. These findings suggests that there are two groups of ITP patients, one with elevated and one with normal of sCD40L. ITP cases in which sCD40L was increased appeared to involve changes in platelet counts and monocyte activation. The pathogenesis of ITP may in some patients include alterations of the CD40/CD40L pathway.
Furthermore, I have attached 1 more huge piece of information from a medical journal that can help you get ITP as a possible indication for Leronlimab.
"Pulsed high-dose dexamethasone modulates Th1-/Th2-chemokine imbalance in immune thrombocytopenia"
This is an excerpt from the medical paper (Journal of Translational Medicine, October 2016)
CCL5 is a CC chemokine that activates cells by binding to Th1-associated CCR1 and CCR5.
CCR5 interaction has been reported in a number of Th1-associated diseases, such as rheumatoid arthritis, multiple sclerosis [32], human immunodeficiency virus 1 (HIV-1) infection [33], Crohn’s disease [7], and oral lichen planus [8].
In this study, for mRNA levels of CCL5 in PBMCs, no significant difference was found between any group; however, plasma levels of CCL5 in active ITP patients was lower than in controls, perhaps because platelets are the principal source of CCL5 [34]. With the increase of platelet counts after pulsed HD-DXM treatment, there was an increase of CCL5 concentration in plasma.
Thus, an important role for CCL5 in the pathogenesis of ITP is not evident; there are possibly other chemokines [35] binding to CCR5 to destroy platelets.
Shouldn't Leronlimab prevent chemokines from binding to CCR5? If this is correct, could this resolve ITP?
Please remember, according to this excerpt, ITP patients had lower levels of CCL5 but when administered dexamethasone, platelet levels began to rise. This confirms restoration of the CCLS (which was decreased) / CCR5 (which was elevated) balance which should alleviate ITP.
To all who have ITP, I am going on record to say that the persistence of ITP is due to the CCL5/CCR5 axis being off. Like I have said, ask your doctor about your RANTES levels in your blood. I GUARANTEE on my health that you will find that it will be elevated. Furthermore, I guarantee that if you bring your RANTES levels down in your blood, you will see your platelets return to normal. Leronlimab restores homeostasis and when administered, I believe can resolve ITP.
Thank you.
